Glioblastomas are the most aggressive and lethal primary astrocytic tumors of the central nervous system. They account for 60-70% of all gliomas and the majority are diagnosed in male Caucasian patients at advanced age. Genetic analyses of glioblastoma show a great intra-and inter-tumor heterogeneity, which opens up a debate about its cellular origin.
INTRODUCTION

Diverse nature of glioblastoma
The term "glioma" refers to a type of brain tumour which originates in the parenchyma of the central nervous system, more precisely from the supportive glial cells -ependymal cells, astrocytes and oligodendrocytes. According to the cell type they originate from or share histological features with, gliomas are divided into ependymomas, astrocytomas and oligodendrogliomas. Of these, astrocytomas are the most common type of glial tumours. The World Health Organization divides gliomas into four grades starting from pilocytic astrocytoma (grade I), diffuse astrocytoma (grade II), anaplastic astrocytoma (grade III) and glioblastoma (grade IV) (1, 2) . Grades III and IV are considered high grade gliomas and represent the majority of brain tumours (3) . Glioblastomas are astrocytic tumours with necrosis and microvascular proliferation. Patients suffering from the most malignant type, glioblastoma, usually succumb to the disease in 12 to 18 months after diagnosis (4) . Although glioblastoma incidence is very low among all cancer types, 1 per 10 000 cases, with 16% of all the primary brain tumour cases it is the most common brain malignancy which is almost always lethal (5, 6) . According to the malignant progression there are two types of glioblastomas -primary, originating de novo, and secondary, evolving from lower-grade gliomas. Based on the presence or absence of isocitrate dehydrogenase (IDH) 1 and 2 gene mutations and chromosome 1p/19q codeletion, in adults, primary glioblastomas are also defined as IDH-wild type, while secondary can either be IDH-mutant and 1p/19q intact, or IDH-mutant and 1p/19q codeleted (7, 8) . The most frequent IDH1 mutations are at codon 132 -in 90% of the cases the mutation is R132H. Other known mutations are R132C, R132G and R132S (9) . IDH2 mutations are less frequent and occur at codon 172, with R172K being the most common. Primary IDH wild type glioblastomas present with mutations in TERT, PTEN and TP53 as well as amplification of EGFR, PDGFRA, CDK4, CDK6, MDM2 and MDM4, 4 while secondary glioblastomas show mutations in IDH, TP53 and ATRX, as well as CDKN2A deletion (10) (11) (12) . IDH mutations are believed to be the among the first changes that occur in gliomagenesis, and are most commonly accompanied by TP53 and ATRX mutations (13) .
ATRX enables incorporation of histone variant H3.3 into heterochromatin, which results in changes in telomere length and genomic instability (6) . A study by Reuss et al. reports existence of three distinct glioblastoma sets: chromosome 7p gain and 10q loss with absence of IDH mutations and presence of nuclear ATRX expression; nuclear ATRX loss and/or IDH mutations; and nuclear ATRX loss with H3F3A mutations without IDH mutations -an adult glioblastoma subset with similarities to paediatric glioblastoma (14) . In addition, expression profiling of glioblastoma specimens defines four different molecular subtypes. A large scale genomic study by Verhaak et al. analysed more than 200 glioblastoma samples from three gene expression platforms (Affymetrix HuEx, Affymetrix U133A and Agilent 244K arrays) and identified four robust clusters: classical, mesenchymal, neural and proneural -subtype names were chosen based on the expression of signature genes (15) . The distinct genetic events of each subtype were identified by analysing data available from The Cancer Genome Atlas Research Network and are presented in Figure 1 (9, (15) (16) (17) (18) (19) (20) .
With a bioinformatics approach, Wang et al. identified 1520 differentially expressed genes in glioblastoma compared to non-tumour glial cells of epilepsy patients (21) . In their work, the pathways most commonly associated to upregulated genes were Wnt, MAPK and ErbB signalling, while p53 signalling, ECM-receptor interaction and antigen processing and presentation were associated with downregulated genes. Of these, Wnt signalling plays a key role in neurogenesis and embryonic brain development, and is able to modulate self-renewal and differentiation of adult tissue stem cells (22) . Also, Wnt signalling pathway is commonly dysregulated in tumorigenesis (23) . In addition, abnormal activation of the Wnt signalling leads to glioblastoma growth and invasion (24) . The TCF/LEF family of Wnt signalling transcription factors has also been correlated to glioblastoma malignancy (23) .
Immunohistochemical staining of glioblastomas resulted in strong expression of TCF-1 and LEF-1 in 51.6% and 71% of analysed samples, respectively. The study by Pećina-Šlaus et al. 
Glioblastoma cellular origin
Glioblastomas can arise anywhere in the central nervous system; proneural and neural subtypes arise in or near the subventricular zone, mesenchymal and classical subtypes are distal to the subventricular zone, other gliomas arise in the superficial subcortical white matter, while proneural glioblastomas with IDH mutations are more likely to occur in the frontal lobes (5, 8) . Such correlation between tumour subtype and intracranial location can be 6 as a result of different cell origin. Glioblastoma cellular origin is controversial and still a matter of debate, where two theories dominate the field: dedifferentiation theory and stem cell theory ( Figure 2 ).
The first proposed mechanism of glioblastoma origin is the "dedifferentiation theory or stochastic model" which states that all cells are equipotent, but under different genetic or epigenetic stimuli some of them can contribute to tumour growth (32, 33) . In the past, it was thought that the adult brain does not regenerate and astrocytes were considered the only dividing cells in the adult brain. In addition to this, the GFAP astrocytic marker was frequently found in glioma tissues, which led to the conclusion that astrocytes are the cells of origin of gliomas as reported by Jiang and Uhrbom (1). This theory was questioned after the discovery of self-renewing and multipotent neural stem cells in the late 1990s, which have been successfully isolated from subventricular zone, hippocampus and dentate gyrus of the adult mammalian brain (34) (35) (36) . Neural stem cells express surface markers nestin, SOX2, CD133 and GFAP (8) . Gliomas arise near the subventricular zone which is consistent with the location of neural stem cells in the mammalian brain and this is why neural stem cells were proposed as the cells of origin of gliomas. Furthermore, alterations of EGFR and AKT/PKB signalling pathways, which are important for neural stem cell proliferation and differentiation, are commonly altered in gliomas. At last, oligodendrocyte precursor cells were proposed as the cells of origin of gliomas for several reasons: they are the major dividing cells in adult brain, they can give rise to oligodendrocytes and they are present in the subventricular zone, white and grey brain matter (1). This hypothesis was supported by the frequent alterations in the PDGFRα signalling pathway in gliomas -a pathway which is important for normal oligodendrocyte development. Moreover, oligodendrocyte precursor cell markers NG2, OLIG2 and PDGFR are found in gliomas which proposes a direct link between the tumours and oligodendrocyte precursor cells. The regenerative potential of astrocytes, neural stem cells and oligodendrocyte precursor cells makes them candidates for cells of origin of gliomas (37) . Still, despite all evidence pointing in the directions of these cells, glioblastoma origin remains unsolved.
The second mechanism is the so called "hierarchical model or stem cell theory" which argues that tumours contain a subset of cells, named cancer stem cells, which are able to proliferate, give rise to and reseed a tumour. Cancer stem cells are described as cells able to self-renew and generate more differentiated tumour cells which is believed to be accomplished by asymmetric division -one daughter cells retains stem cell properties while the other differentiates into different types of tumour cells (38) . Cancer stem cells have been proven as more resistant to genotoxic treatments which seems to be the cause for tumour recurrence (34, 38) . Their resistance to radiation is a result of the higher DNA repair rate as presented by CD15 has also been proposed as a glioma stem cell marker (44, 45) . Still, the "gold standard"
for identification of cancer stem cells is their ability to give rise to a phenotypically identical tumour as the primary malignancy in immunocompromised mice.
In the case of glioblastomas, it is highly likely that multiple cell lineages are simultaneously present in the tumour. This also suggests that various cell types are responsible for glioma initiation and development. It is thus important to continue investigating glioma cellular origin and how specific cell types can contribute to glioma formation, progression and recurrence (1).
Clinical management and molecular biomarkers
The late glioblastoma discovery is a result of its unspecific symptoms (headache, confusion, memory loss and personality changes) which can be accompanied by problems in motor function and speech (46) . Diagnosis is performed with computer tomography and magnetic resonance imaging or magnetic resonance spectroscopy, and is confirmed with molecular techniques including immunohistochemistry, Sanger sequencing, fluorescence in situ hybridization and microsatellite analysis (47) . Standard of care consists of maximal surgical resection followed by radiation and temozolomide chemotherapy (48, 49) . However, even with such an aggressive treatment in 75% -90% of the glioblastoma cases, the tumour recurs within 7 to 10 months after surgery. Only 9% of glioblastoma patients are still alive 2 years post diagnosis and these are considered long-term survivors (50) . Major issues in glioblastoma management are its intracranial location, fast growth, infiltrative nature that leads to incomplete surgical resection, and development of therapy resistance (37) . Also, 
Long term survivors
Gliomas can occur at any age, but the majority arise in older patients. Primary glioblastomas are more common among Caucasian men in advanced age, while lower grade gliomas and secondary glioblastomas are more common in younger adults (aged 45 years and younger) (55) . Gender differences are attributed to hormonal changes and genetic features (8) . Due to frequent disease recurrence, only 3 to 5% of patients live longer than 3 years after diagnosis (56) . Prognosis depends on patients' age at diagnosis with younger patients having better outcome. This can be partially explained with better overall health, but can also be a result of Their systematic review reports 0.71% of all patients present with survival longer than 10 years. Moreover, the authors found a relationship between age at diagnosis and overall survival -for every 4.7 years younger age at diagnosis the overall survival is one year longer after 10 years of survival. In general, 10-year overall survival varies among age groups: 0 -14, 15 -39 and 40+ years present with 14.9%, 13.6% and 1.6% long term survivors, respectively. Another investigated factor is the most common clinical symptom of glioblastoma -epileptic seizures. Seizures can either occur as part of the initial diagnosis or as a result of recurrence of the disease. Although they reduce the quality of life, seizures as a 11 symptom are found to be positively correlated to longer survival (60) (61) (62) . However, in cases of a longer delay between epileptic seizures as a symptom and the surgical resection, this correlation does not seem to be significant (62, 63) .
When it comes to the genetics, reports show glioblastomas with IDH1/2 mutations and MGMT promotor methylation are more responsive to surgical resection and temozolomide chemotherapy, and have better prognosis (57, (64) (65) (66) In general, younger age is a predictor of better overall survival. Patients diagnosed with glioblastoma below the age of 40 years have a greater chance for long survival, especially above 10 years after diagnosis (76, 77) . Another factor affecting the prognosis is the extent of the surgical resection -12 months progression free survival is increased by 50% with complete tumour resection. However, there are also reports of patients with incomplete resection or biopsy only that survived for more than a decade (59) . Besides age and good performance status at diagnosis, adjuvant chemotherapy is also considered beneficial (58).
Epileptic seizures are also favourable, probably due to the possibility of an earlier stage diagnosis, when the tumour is smaller and the chance for a total resection is higher.
Regarding the genetic factors, patients with MGMT promoter methylation and IDH1/2 mutations are more common among long term survivors.
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CONCLUSION
Glioblastoma is a big medical problem of modern society because of its high mortality rate.
Even with aggressive clinical care, long-term glioblastoma survivors comprise less than 15% of all cases. Further extensive research and multidisciplinary "omics" approach will be needed for understanding the natural causes of glioblastoma occurrence. Clinical features like age at diagnosis, presence of seizures as an initial symptom, and extent of surgical resection are known factors that contribute to patient' life expectancy. However, for better patient management, genetic, epigenetic, transcriptomic and proteomic information should be added to the appearance of early clinical symptoms. So far, IDH mutations and MGMT promoter methylation are the most important molecular factors for determining glioblastoma longevity.
Revealing the factors that contribute to patients' longevity is important for precise diagnosis and correct clinical management of the disease. Due to the small number of patients with long life expectancy, comparative studies about genetic differences between short-and long-term survivors are challenging which makes this phenomenon poorly understood. However, identification of such differences is crucial for establishing the mechanism of glioblastoma pathology. 
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